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W
hen arteriovenous malforma-
tions (AVMs) of the brain were
first described in the middle of
the 19th century, deciding on treatment
was easy, because there was none. Since
the first reports of the neurosurgical
exposure of brain AVMs at the end of
that century,1 2 their management has
been dogged by controversy. In 1928,
Cushing and Bailey wrote, ‘‘…to extir-
pate one of these aneurysmal angiomas
in its active state would be unthink-
able…’’,3 but, while their book was in
press, Walter Dandy published a case
series of people whose brain AVMs had
been surgically resected (with variable
success).4 Later developments in cathe-
ter angiography, bipolar coagulation,
the operating microscope, and stereo-
tactic surgery have all encouraged sur-
gical intervention and no doubt
improved the completeness and safety
of resection.5 6 However, clinicians still
struggle with the original dilemma of
whether some brain AVMs should be
treated at all.
Interventions for brain AVMs diversi-
fied during the latter half of the 20th
century, giving clinicians a further
dilemma about which intervention to
use should treatment be appropriate.
Endovascular embolisation, by injecting
artificial agents in the afferent feeding
vessels of brain AVMs, was first reported
in 1960.7 The technique has been refined
ever since, initially as an adjunct to
neurosurgical excision,8 but more
recently, with the development of
microcatheters and liquid polymer
glues, as a potentially curative proce-
dure.9 Unfractionated stereotactic radio-
therapy, confusingly referred to as
"radiosurgery" by some, was first used
to treat brain AVMs a decade after the
first report of endovascular embolisa-
tion.10 Stereotactic radiotherapy, using
gamma knife, linear accelerator, and
charged particle (proton beam) techni-
ques, can provoke vascular obliteration
of compact brain AVMs (3 cm in
diameter and of larger AVMs that
have been reduced to this size with
embolisation. Despite the chronology of
the development of these interventions,
there are far more large published
studies of stereotactic radiotherapy than
of embolisation and surgery put
together.
SHORTAGE OF EVIDENCE
So, how good is the evidence for the
beneficial and adverse effects of these
treatments?11 What is the balance
between them? Which brain AVMs
should be treated, and with what? A
single randomised controlled trial (RCT)
found no major differences between n-
butyl-cyanoacrylate (n-BCA) liquid and
polyvinyl alcohol particles in the pre-
operative embolisation of brain AVMs.12
A similar RCT of Onyx (a new non-
adhesive liquid embolic material) versus
n-BCA in the pre-operative embolisation
of brain AVMs has been completed but
not published (G Duckwiler, UCLA
Medical Center, personal communica-
tion). Both of these RCTs were funded
by industry, they did not appear to be
powered to test equivalence of the
interventions, and were conducted to
obtain USA Food and Drug
Administration approval for the embolic
agents. Otherwise, there are no RCTs
whatsoever.
The remainder of the vast literature
about the benefits and risks of treating
brain AVMs is composed of case series
without even a concurrent control
group.11 These studies have frequently
been retrospective and participants were
amassed over long periods of time,
during which technical developments
in treatment occurred. Moreover, the
people in these case series were usually
selected for a particular intervention, or
rejected from the other interventions
available, on the basis of the vascular
anatomy ("angioarchitecture") of the
brain AVM.13 Therefore, the inevitable
heterogeneity of angioarchitecture
between these series makes their com-
parison with each other difficult, if not
impossible. Even the description of the
effects of a single modality of treatment
in these series has been complicated by
the inclusion of people who had already
received one or more of the other inter-
ventions. Most of these studies have not
used standard, independently assessed
measures of morbidity, disability or
dependence. Rather, by using the occur-
rence of haemorrhage during follow up
as the main outcome instead, these
studies may have completely missed
disability from other causes (such as
radiation induced damage14), or conver-
sely, overestimated morbidity because
haemorrhage from a brain AVM may
only be disabling for the minority of
people.15 Without a control group, it has
been difficult to reliably ascertain
whether any change in haemorrhage
rate after treatment is an improvement
on conservative management.14
Moreover, the popular comparison of
haemorrhage rates before and after
intervention14 may simply reflect the
waning of the haemorrhage rate after a
bleed at initial presentation,16 17 often
obscured because treatment outcomes
have not been stratified by initial pre-
sentation. Another unsatisfactory pri-
mary outcome after treatment,
extensively used in studies of stereo-
tactic radiotherapy,18 has been brain
AVM "obliteration" (lack of visualisation
on angiography); this tells us nothing
about disability, and brain AVMs have
been reported to recanalise after appar-
ent obliteration, especially in the rare
studies where follow up has been




Criticisms of the literature aside, we can
make some tentative generalisations:
N Cure (judged by apparent obliteration
on angiography) has been least com-
mon among people selected for
embolisation, greater for those
selected for stereotactic radiotherapy,
and greater still for those selected for
surgery.
N A review of the effects of surgical
excision since the 1970s found overall
post-operative case fatality to be,3%
and permanent "morbidity" to affect
,9%.19 These findings are compar-
able to the Columbia AVM study
group cohort where ,6% of people
were judged (independently, by a
neurologist) to have a disabling
neurological deficit 1 year after sur-
gery.6
N These surgical studies broadly con-
firmed that the main components of
the 5 point Spetzler-Martin grading
system (table 1) predict postoperative
outcome, which is generally very
good for grade I to III brain AVMs.20
N For endovascular embolisation alone,
,10 months after treatment, case
fatality was 1%, and 13% of people
in the Columbia AVM study group
cohort were judged (independently,
by a neurologist) to have new
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neurological deficits (which were not
predicted by the Spetzler-Martin
grading system, but rather by
increasing age and increasing num-
ber of embolisations).21
N For stereotactic radiotherapy alone,
,34 months after treatment, case
fatality was 0.2%, and radiation
injury affected ,6% (which was
disabling for ,2% of the whole
group).22
N While minimum radiation dose and
AVM size predict the probability of
obliteration, complications vary by




UNTREATED CLINICAL COURSE IS
UNSATISFACTORY
Unfortunately, clinicians have to make a
treatment decision, based on an indirect
comparison of these "average" treatment
outcomes with the "average" untreated
clinical course for people with a brain
AVM. Data on specific predictors of
outcome for any individual person are
limited. Furthermore, the few cohorts
that provide reliable data about
untreated clinical course have usually
consisted of brain AVMs that were
impossible or unsuitable to treat, out-
come has seldom been segregated
according to mode of presentation,
follow up has been short, and methods
of analysis have differed.24 Even the two
most recent studies of whether initial
presentation with haemorrhage confers
a worse prognosis for subsequent hae-
morrhage do not concur.16 25 It is, how-
ever, likely that initial presentation with
intracranial haemorrhage and deep
venous drainage do confer a higher risk
of subsequent haemorrhage for
untreated brain AVMs,16 17 at least in
the first few years after presentation.
The well recognised heterogeneity in
prognosis for haemorrhage among brain
AVMs is starting to be understood, and
this probably invalidates popular for-
mulae that estimate someone’s lifetime
risk of haemorrhage based on the
incorrect assumption that the annual
risk of haemorrhage is constant.26
Brain AVMs now pose a regular
management problem because our
ignorance of their true clinical course
has been overshadowed by the interest
in and pace of development of surgical,
endovascular, and radiation interven-
tions, the seemingly favourable short
term effects of these treatments for
most people, and their widening avail-
ability. However, these treatments are
costly, especially for people whose brain
AVMs are more difficult to treat and
who have worse outcomes,27 and there is
likely to be variation between specialist
centres and different countries in which
treatments are used, according to local
opinion, expertise, and treatment avail-
ability.
Not surprisingly, therefore, there is
still disagreement about whether to
treat people with brain AVMs at all,
and if so, which intervention(s) to use.
TO TREAT OR NOT
Ideally, any treatment decision should
be taken by a multidisciplinary team
composed of a neurologist, neurosur-
geon, radiotherapist, and neuroradiolo-
gist. Whether to treat a brain AVM now
seems fairly straightforward if it has
been detected following an intracranial
haemorrhage; the early risk of re-bleed-
ing makes intervention justified for all
but those AVMs that are impossible to
treat and those people who are so
disabled, so elderly, or so burdened with
other comorbidities that "conservative
management" is desirable because treat-
ment would not be beneficial. More
than half of brain AVMs come to
medical attention with problems other
than intracranial haemorrhage,28 and
informing these people’s choices about
treatment is difficult because of the
inadequacies of the available data. A
landmark, albeit post hoc, analysis of
the Columbia AVM cohort, so far only
published as an abstract, suggests that
the interventional treatment of unrup-
tured brain AVMs is actually more likely
to result in subsequent haemorrhage
and/or disability than conservative man-
agement over ,5 years follow up.29 This
observation has reinforced the proposal
for a much needed RCT (ARUBA),
which will compare interventional treat-
ment of unruptured brain AVMs with
their conservative management.
Potential collaborators are encouraged
to visit the ARUBA study website
(http://www.arubastudy.org) to register
their interest.
TO TREAT WITH WHAT
Once a decision to intervene has been
made, clinicians are faced with the final
dilemma of exactly how to treat a brain
AVM and any associated aneurysms.
There is considerable uncertainty about
which intervention to use when a brain
AVM has ruptured at presentation and
is amenable to more than one of the
available treatments, so we hope that
ARUBA will not be the only RCT of
interventions for brain AVMs. For now,
clinicians can defer to management
guidelines that reflect current practice
in North America, but are likely to be
less representative of practice in other
parts of the world. These guidelines
have recommended an approach accord-
ing to the Spetzler-Martin grade of the
brain AVM, and the main recommenda-
tions are:20 30
N Surgical excision should be consid-
ered as the primary single treatment
for grade I and II brain AVMs.
N Surgery alone is unsuitable for grade
IV and V brain AVMs.
N Stereotactic radiotherapy is the pre-
ferred single treatment for small
((3 cm diameter) grade I and II
brain AVMs if the vascular anatomy
is unsuitable for surgery.
N A combined approach to completely
eradicate the brain AVM nidus using
embolisation (perhaps repeatedly)
prior to surgery or stereotactic radio-
therapy is the treatment of choice for
other suitable grade II–V lesions.
N Palliative embolisation (without
complete brain AVM eradication)
may be beneficial for intractable
epilepsy refractory to best antiepilep-
tic drug treatment, or when a pro-
gressive neurological deficit is
thought to be due to high flow or
venous hypertension.
The authors of these guidelines
acknowledge that their recommenda-
tions are based on non-randomised
evidence.30 Technological advances in
the treatment of brain AVMs, leading
to risk/benefit ratios that are compar-
able among the three main interven-
tions for some people, are likely to
perpetuate uncertainty in the choice of
treatment. The heterogeneity of brain
AVMs, the relative infrequency of their
outcome events, and the strong beliefs
held by some interventionists will pro-
vide exciting challenges for trialists.
However, the recent International
Subarachnoid Aneurysm Trial provides
an encouraging example for the RCTs
that are needed to address both whether




Small (,3 cm) 1
Medium (3–6 cm) 2
Large (.6 cm) 3
Eloquence of adjacent brain*
Not eloquent 0
Eloquent 1
Pattern of venous drainage
Superficial only 0
Deep 1
Grade = total of scores. *Eloquent:
sensorimotor, language and visual cortex;
hypothalamus and thalamus; internal
capsule; brainstem; cerebellar peduncles;
and deep cerebellar nuclei. Superficial:
cortical venous system and cerebellar
hemispheric veins (that drain directly into the
straight or transverse sinuses).
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